読み込み中
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
前日終値
$1.30
−$0.01 · -0.76%
日中の時刻はETです。市場データは遅延する場合があります。
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
日中レンジ
現在 $1.30
52週レンジ
現在 $1.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
55
まちまち
リスク
66
高リスク
モメンタム
50
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
日中レンジ
現在 $1.30
52週レンジ
現在 $1.30
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上原価 | 52.53万 USD | — | — | — | — |
| 粗利益 | −52.53万 USD | — | — | — | — |
| 研究開発 | 4.71兆 USD | 554.91万 USD | 543.73万 USD | 639.24万 USD | 578.49万 USD |
| 販売・一般管理 | 3.6兆 USD | 404.25万 USD | 307.88万 USD | 255.11万 USD | 232.87万 USD |
| 営業費用 | 778.11万 USD | 959.16万 USD | 851.61万 USD | 894.35万 USD | 811.36万 USD |
| 受取利息 | 8.79万 USD | 12.48万 USD | 27.18万 USD | 35.58万 USD | 1.19万 USD |
| 支払利息 | — | — | 4.98万 USD | 938 USD | 5123 USD |
| 減価償却費と償却費 | 52.53万 USD | 74.38万 USD | 75.9万 USD | 74.75万 USD | 72.33万 USD |
| 営業利益 | −830.64万 USD | −959.16万 USD | −851.61万 USD | −894.35万 USD | −811.36万 USD |
| 純利益 | −821.85万 USD | −946.7万 USD | −829.41万 USD | −858.86万 USD | −810.69万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年9月24日 | 1:20 | — | — |
株式分割 | 2013年9月10日 | 2:7 | — | — |
発効済み 2019年9月24日
1:20
発効済み 2013年9月10日
2:7
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
